1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

MDS - 838

Updated Phase 2 Results of Elritercept in Patients With Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms

Rami Komrokji

Poster Presenter: Rami Komrokji

$Thumbnail for Updated Results from Randomized Phase II Dose Optimization Study of Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)$

MM - 1831

Updated Results from Randomized Phase II Dose Optimization Study of Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)

Nisha Joseph

Poster Presenter: Nisha Joseph

SOHO 2026 Annual Meeting

Posters by Title

Updated Phase 2 Results of Elritercept in Patients With Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms

Updated Results from Randomized Phase II Dose Optimization Study of Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)

Updated Results From the Phase 2 IZALCO Study: Efficacy and Safety of Isatuximab Subcutaneous Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Updated Results From the Phase 3 ECHO Trial of Bendamustine-Rituximab With or Without Acalabrutinib in Patients With Previously Untreated Mantle Cell Lymphoma: 50 Months of Follow-up

Updated Results of POLARIS-1 (Part 1), a Global Registrational Phase 3 Study: Olverembatinib Combined With Low-Intensity Chemotherapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Updated Safety of Isatuximab Subcutaneous At-Home Administration by On-Body Injector in Relapsed/Refractory Multiple Myeloma in the Phase 3 IRAKLIA Study

Upfront Allogeneic Stem Cell Transplantation With Individualized Venetoclax-Based Conditioning in MECOM-Rearranged Acute Myeloid Leukemia: A Single-Center Retrospective Study

Upfront Pemigatinib for Chronic-Phase Myeloid/Lymphoid Neoplasm with a Novel FGFR1 Rearrangement Presenting as Transient Bilateral Vision Loss: A Case Report.

Upfront Triple Therapy With FLAG-Venetoclax Backbone in Intensive Chemotherapy-Eligible FLT3-ITD Patients With AML: Preliminary Results From a Retrospective Cohort